These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 17896784

  • 1. Positron emission tomography imaging in nonsmall-cell lung cancer.
    Erasmus JJ, Macapinlac HA, Swisher SG.
    Cancer; 2007 Nov 15; 110(10):2155-68. PubMed ID: 17896784
    [Abstract] [Full Text] [Related]

  • 2. Positron emission tomography/computed tomography in lung cancer staging, prognosis, and assessment of therapeutic response.
    Truong MT, Viswanathan C, Erasmus JJ.
    J Thorac Imaging; 2011 May 15; 26(2):132-46. PubMed ID: 21508735
    [Abstract] [Full Text] [Related]

  • 3. Value of FDG PET in the management of NSCLC.
    Ukena D, Hellwig D.
    Lung Cancer; 2004 Aug 15; 45 Suppl 2():S75-8. PubMed ID: 15552785
    [Abstract] [Full Text] [Related]

  • 4. Prognosis and reevaluation of lung cancer by positron emission tomography imaging.
    Erasmus JJ, Rohren E, Swisher SG.
    Proc Am Thorac Soc; 2009 Apr 15; 6(2):171-9. PubMed ID: 19349485
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Positron Emission Tomography (PET) radiotracers in oncology--utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC).
    Miele E, Spinelli GP, Tomao F, Zullo A, De Marinis F, Pasciuti G, Rossi L, Zoratto F, Tomao S.
    J Exp Clin Cancer Res; 2008 Oct 17; 27(1):52. PubMed ID: 18928537
    [Abstract] [Full Text] [Related]

  • 7. Mediastinal nodal staging of nonsmall cell lung cancer using integrated 18F-FDG PET/CT in a tuberculosis-endemic country: diagnostic efficacy in 674 patients.
    Kim YK, Lee KS, Kim BT, Choi JY, Kim H, Kwon OJ, Shim YM, Yi CA, Kim HY, Chung MJ.
    Cancer; 2007 Mar 15; 109(6):1068-77. PubMed ID: 17311309
    [Abstract] [Full Text] [Related]

  • 8. Impact of whole-body ¹⁸F-fluorodeoxyglucose positron emission tomography on therapeutic management of non-small cell lung cancer.
    Heo EY, Yang SC, Yoo CG, Han SK, Shim YS, Kim YW.
    Respirology; 2010 Nov 15; 15(8):1174-8. PubMed ID: 20573060
    [Abstract] [Full Text] [Related]

  • 9. [Detection of unexpected extrathoracic metastases in preoperative staging of non-small-cell bronchial carcinoma (NSCLC) with positron emission tomography (PET)].
    Schmid RA, Hillinger S, Bruchhaus H, Steinert HC, von Schulthess GK, Largiadèr F, Weder W.
    Langenbecks Arch Chir Suppl Kongressbd; 1998 Nov 15; 115():1264-7. PubMed ID: 9931854
    [Abstract] [Full Text] [Related]

  • 10. [Current status of 18F-FDG PET in predicting outcome of cancer therapy].
    Gong HY, Yu JM.
    Zhonghua Zhong Liu Za Zhi; 2004 Oct 15; 26(10):577-80. PubMed ID: 16429617
    [No Abstract] [Full Text] [Related]

  • 11. The additional value of FDG PET imaging for distinguishing N0 or N1 from N2 stage in preoperative staging of non-small cell lung cancer in region where the prevalence of inflammatory lung disease is high.
    Turkmen C, Sonmezoglu K, Toker A, Yilmazbayhan D, Dilege S, Halac M, Erelel M, Ece T, Mudun A.
    Clin Nucl Med; 2007 Aug 15; 32(8):607-12. PubMed ID: 17667432
    [Abstract] [Full Text] [Related]

  • 12. Non-small cell lung cancer: FDG-PET imaging.
    Erasmus JJ, McAdams HP, Patz EF.
    J Thorac Imaging; 1999 Oct 15; 14(4):247-56. PubMed ID: 10524805
    [Abstract] [Full Text] [Related]

  • 13. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.
    Hoekstra CJ, Stroobants SG, Smit EF, Vansteenkiste J, van Tinteren H, Postmus PE, Golding RP, Biesma B, Schramel FJ, van Zandwijk N, Lammertsma AA, Hoekstra OS.
    J Clin Oncol; 2005 Nov 20; 23(33):8362-70. PubMed ID: 16293866
    [Abstract] [Full Text] [Related]

  • 14. The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology.
    Vansteenkiste JF, Stroobants SG.
    Eur Respir J; 2001 Apr 20; 17(4):802-20. PubMed ID: 11401078
    [Abstract] [Full Text] [Related]

  • 15. [Value of 18F-fluorodeoxyglucose positron emission tomography imaging in staging of non-small cell lung cancer].
    Guan Y, He S, Dong J.
    Zhonghua Yi Xue Za Zhi; 2001 Oct 20; 81(19):1180-3. PubMed ID: 11769705
    [Abstract] [Full Text] [Related]

  • 16. FDG-PET for lymph node staging in NSCLC: a major step forward, but beware of the pitfalls.
    Vansteenkiste JF.
    Lung Cancer; 2005 Feb 20; 47(2):151-3. PubMed ID: 15639713
    [No Abstract] [Full Text] [Related]

  • 17. [18F]Fluorodeoxyglucose PET in Thoracic Malignancies.
    Vilstrup MH, Torigian DA.
    PET Clin; 2014 Oct 20; 9(4):391-420, v. PubMed ID: 26050944
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The use of positron emission tomography (PET) in the staging/evaluation, treatment, and follow-up of patients with lung cancer: a critical review.
    Mac Manus M, Hicks RJ.
    Int J Radiat Oncol Biol Phys; 2008 Dec 01; 72(5):1298-306. PubMed ID: 19028270
    [No Abstract] [Full Text] [Related]

  • 20. PET-CT in the staging and treatment of non-small-cell lung cancer.
    Ibeas P, Cantos B, Gasent JM, Rodríguez B, Provencio M.
    Clin Transl Oncol; 2011 Jun 01; 13(6):368-77. PubMed ID: 21680297
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.